Global Biosimilar Monoclonal Antibodies Market Size is valued at USD 7.8 Billion in 2024 and is predicted to reach USD 32.1 Billion by the year 2034 at a 15.3% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Biosimilars are biological drugs, and they are large, complex biological molecules produced from living organisms that are often difficult to characterize and therefore difficult to copy. Monoclonal antibody biosimilars play a vital role in treating various chronic and autoimmune diseases. They also represent an opportunity to increase access and reduce costs for patients and healthcare systems.
Global Biosimilar Monoclonal Antibodies market growth is attributed to numerous factors such as biosimilar monoclonal antibodies market include the increasing patent expiries of mAbs, innovation of advanced mAbs, the growing number of biosimilars for oncology treatments, rising demand for lower-priced, cost-efficient biosimilar monoclonal antibodies, growing chronic and autoimmune diseases like cancer, rheumatoid arthritis, diabetes, and the rising older population. Moreover, increasing R&D investments for biological drugs are anticipated to fuel market adoption during the forecast period. Growing R&D activities result in innovative drug products, developmental procedures, and healthcare facilities, thereby boosting market growth.
However, the high cost of development processes, complex mAb manufacturing procedures, region-specific government rules regarding the production and use of biosimilars, lack of scientific standards for biosimilars are expected to hamper the market's growth in the coming years.
The Biosimilar Monoclonal Antibodies Market is segmented based on product, indication, and region. By product, the market comprises the infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products. The infliximab and rituximab segments are projected to hold the highest market share over the forecast period owing to their increasing use in treating various chronic and autoimmune diseases. The market is classified into oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications based on the indication. Among all, The oncology segment is predictable to dominate the market in the coming years due to the surge in biosimilar mAbs approvals for cancer treatments. Regionally, the market is categorized across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America region dominated this market in 2020 and is expected to continue its trend over the forecast period on account of the favourable reimbursement policies, increasing patent expiration, and the growing rate of biosimilar mAbs approvals.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 7.8 Billion |
| Revenue Forecast In 2034 | USD 32.1 Billion |
| Growth Rate CAGR | CAGR of 15.3% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn, and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products, By Indication |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, Intas Pharmaceuticals Limited, Genor BioPharma Co., Ltd, BIOCAD, Reddys Laboratories Ltd, 3SBio, Reliance Life Sciences, Hisun Pharma, Celgen Biopharma, Torrent Pharmaceuticals, Cadila Healthcare, Mylan Inc., BioXpress Therapeutics SA, Celltrion, EirGenix, Inc., Teva Pharmaceutical Industries Ltd., ALTEOGEN Inc., Apotex (Apobiologix), AryoGen Pharmed, Prestige BioPharma (PBP), PlantForm Outlook Therapeutics (Oncobiologics), Shanghai CP Guojian Pharmaceutical, Shanghai Henlius Biotech, Stada Arzneimittel AG, Other Prominent Players |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Biosimilar Monoclonal Antibodies Market Snapshot
Chapter 4. Global Biosimilar Monoclonal Antibodies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Clinical Trial/Pipeline Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Infliximab
5.2.2. Trastuzumab
5.2.3. Rituximab
5.2.4. Adalimumab
5.2.5. Bevacizumab
5.2.6. Ranibizumab
5.2.7. Denosumab
5.2.8. Eculizumab
5.2.9. Filgrastim
5.2.10. Pegfilgrastim
5.2.11. Ustekinumab
5.2.12. Other Pipeline drugs
Chapter 6. Market Segmentation 4: By Indications Estimates & Trend Analysis
6.1. By Indications & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:
6.2.1. Autoimmune Diseases
6.2.2. Oncology
6.2.3. Ophthalmic Disorders
6.2.4. Bone Disorders
6.2.5. Rare Hematologic/Neurologic Disorders
6.2.6. Hematologic Support
6.2.7. Inflammatory Bowel Disease
6.2.8. Other Indication
Chapter 7. Biosimilar Monoclonal Antibodies Market Segmentation 5: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
7.1.2. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts By Types, 2021-2034
7.1.3. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.1.4. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034
7.2.2. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034
7.2.3. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.2.4. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034
7.3.2. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034
7.3.3. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.3.4. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034
7.4.2. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034
7.4.3. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.4.4. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034
7.5.2. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034
7.5.3. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
7.5.4. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Accord BioPharma Inc.
8.2.2. Alvotech USA Inc.
8.2.3. Amgen Inc.
8.2.4. Amneal Pharmaceuticals LLC
8.2.5. Biocon Biologics Inc.
8.2.6. Biogen Netherlands B.V.
8.2.7. Biosimilar Collaborations Ireland Limited
8.2.8. Bio-Thera Solutions, Ltd.
8.2.9. Boehringer Ingelheim Pharmaceuticals, Inc.
8.2.10. Celltrion Healthcare Hungary Kft.
8.2.11. Coherus BioSciences, Inc.
8.2.12. CuraTeQ Biologics s.r.o
8.2.13. Eli Lilly and Company
8.2.14. FGK Representative Service GmbH
8.2.15. Formycon AG
8.2.16. Fresenius Kabi
8.2.17. Gedeon Richter Plc.
8.2.18. Hexal AG
8.2.19. Hong Kong King-Friend Industrial Company Limited
8.2.20. Hospira Inc., a Pfizer Company
8.2.21. Juta Pharma GmbH
8.2.22. Kashiv BioSciences, LLC
8.2.23. Mabxience Research SL
8.2.24. Medice Arzneimittel Pütter GmbH Co. KG
8.2.25. Midas Pharma GmbH
8.2.26. Mundipharma Corporation (Ireland) Limited
8.2.27. Pfizer Inc.
8.2.28. Qilu Pharma Spain S.L.
8.2.29. Ratiopharm GmbH
8.2.30. Reddy Holding GmbH
8.2.31. Samsung Bioepis Co., Ltd.
8.2.32. Sandoz Inc.
8.2.33. Sanofi
8.2.34. Stada Arzneimittel AG
8.2.35. Strides Pharma (Cyprus) Limited
8.2.36. Tanvex BioPharma USA, Inc.
8.2.37. Techdow Pharma Netherlands B.V.
8.2.38. Teva GmbH
8.2.39. Theramex Ireland Limited
8.2.40. Other prominent players
Global Biosimilar Monoclonal Antibodies Market, by Product,
Global Biosimilar Monoclonal Antibodies Market, by Indication, Autoimmune Diseases
Global Biosimilar Monoclonal Antibodies Market, by Region,
North America Biosimilar Monoclonal Antibodies Market, by Country,
Europe Biosimilar Monoclonal Antibodies Market, by Country,
Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country,
Latin America Biosimilar Monoclonal Antibodies Market, by Country,
Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country,